Unaudited Financial Results for the quarter ended 30th September, 2025 are attached.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cravatex Ltd reported Q2 FY26 standalone revenue from operations of ₹252.58 lakhs vs ₹225.83 lakhs YoY, but standalone profit after tax plunged to ₹33.02 lakhs from ₹210.51 lakhs due to a sharp drop in other income (₹125.56 lakhs vs ₹345.64 lakhs). On a consolidated basis, Q2 FY26 revenue from operations fell to ₹5,144.52 lakhs from ₹5,503.62 lakhs YoY, but consolidated PAT attributable to owners jumped to ₹521.60 lakhs from ₹265.02 lakhs. For H1 FY26, consolidated revenue declined to ₹7,457.21 lakhs vs ₹8,081.22 lakhs, while consolidated PAT rose modestly to ₹384.83 lakhs from ₹313.40 lakhs. The wholly-owned UK subsidiary BB (UK) Ltd and step-down subsidiary BB Euro GmbH together posted a net loss of ₹307.62 lakhs for the period. Operating cash flow was negative at both standalone (-₹268.55 lakhs) and consolidated (-₹930.91 lakhs) levels in H1 FY26. The statutory auditors issued an unmodified limited review opinion.
The mixed picture — consolidated profit growth driven by parent despite weaker revenue and losses at UK/German subsidiaries — combined with negative operating cash flows at both levels, may keep investors cautious. The sharp standalone PAT decline and subsidiary losses are key concerns for shareholders.